Multiple autoimmune complications after a single dose of Pembrolizumab
Ahdi HS, Abdulmujeeb S, Nabrinsky E. Multiple Autoimmune Complications After a Single Dose of Pembrolizumab. Cureus. 2023;15(3):e35871. Published 2023 Mar 7. doi:10.7759/cureus.35871
Pembrolizumab, a monoclonal antibody that inhibits programmed cell death protein-1 (PD-1), is an important treatment for various malignancies. Unfortunately, it has also been associated with a wide array of immune-related adverse events. We present a unique case of a patient who received a single dose of pembrolizumab and subsequently developed multiple immune-mediated complications, including dermatitis, hepatitis, myositis, myocarditis, and myasthenia gravis.